Autologous stem cell-based cancer immunotherapy - Accurexa/StemImmune

Drug Profile

Autologous stem cell-based cancer immunotherapy - Accurexa/StemImmune

Alternative Names: Autologous stem cell-mediated cancer therapeutic - Accurexa/StemImmune; Autologous stem cell-mediated immunotherapy - Accurexa/StemImmune

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator StemImmune
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 17 Oct 2016 Accurexa and StemImmune agree to co-develop stem cell-mediated immunotherapy In USA for Cancer
  • 17 Oct 2016 Phase-I clinical trials in Cancer in USA (Parenteral) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top